BR112016012671A2 - Composição para reduzir distúrbios do envelhecimento da pele compreendendo um retinaldeído e um extrato de leontopodium alpinum - Google Patents

Composição para reduzir distúrbios do envelhecimento da pele compreendendo um retinaldeído e um extrato de leontopodium alpinum

Info

Publication number
BR112016012671A2
BR112016012671A2 BR112016012671A BR112016012671A BR112016012671A2 BR 112016012671 A2 BR112016012671 A2 BR 112016012671A2 BR 112016012671 A BR112016012671 A BR 112016012671A BR 112016012671 A BR112016012671 A BR 112016012671A BR 112016012671 A2 BR112016012671 A2 BR 112016012671A2
Authority
BR
Brazil
Prior art keywords
retinaldehyde
composition
skin aging
leontopodium alpinum
reduce skin
Prior art date
Application number
BR112016012671A
Other languages
English (en)
Inventor
Baudier Philippe
Original Assignee
Galephar M/F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar M/F filed Critical Galephar M/F
Publication of BR112016012671A2 publication Critical patent/BR112016012671A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÃO PARA REDUZIR DISTÚRBIOS DO ENVELHECIMENTO DA PELE COMPREENDENDO UM RETINALDEÍDO E UM EXTRATO DE LEONTOPODIUM ALPINUM. A presente invenção diz respeito a uma composição para reduzir distúrbios do envelhecimento da pele compreendendo pelo menos um retinaldeído e/ou um de seus estereoisômeros e pelo menos um extrato de Leontopodium alpinum em um veículo cosmética ou farmaceuticamente aceitável.
BR112016012671A 2013-12-03 2014-12-03 Composição para reduzir distúrbios do envelhecimento da pele compreendendo um retinaldeído e um extrato de leontopodium alpinum BR112016012671A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1362015 2013-12-03
PCT/EP2014/076356 WO2015082520A1 (fr) 2013-12-03 2014-12-03 Composition pour reduire les troubles de la senescence cutanee comprenant un rétinalaldéhyde et un extrait de leontopodium alpinum

Publications (1)

Publication Number Publication Date
BR112016012671A2 true BR112016012671A2 (pt) 2017-08-08

Family

ID=50289873

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012671A BR112016012671A2 (pt) 2013-12-03 2014-12-03 Composição para reduzir distúrbios do envelhecimento da pele compreendendo um retinaldeído e um extrato de leontopodium alpinum

Country Status (9)

Country Link
EP (1) EP3077061B1 (pt)
KR (1) KR20160103983A (pt)
BR (1) BR112016012671A2 (pt)
ES (1) ES2791066T3 (pt)
MX (1) MX2016007295A (pt)
PH (1) PH12016501013A1 (pt)
RU (1) RU2675702C1 (pt)
WO (1) WO2015082520A1 (pt)
ZA (1) ZA201603801B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018077991A1 (en) * 2016-10-27 2018-05-03 Dsm Ip Assets B.V. Method of protecting keratinocytes against the harmful effects of air pollution
WO2019022250A1 (ja) * 2017-07-28 2019-01-31 国立大学法人九州大学 水溶性有効成分の放出が制御された経皮吸収組成物
KR102116482B1 (ko) * 2020-02-27 2020-05-28 주식회사 한국화장품제조 안티폴루션 유화물이 담지된 화장료 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782919B1 (fr) * 1998-09-04 2001-05-25 Roc Sa Composition contre le vieillissement et son utilisation
CH694611A5 (de) * 2000-05-16 2005-04-29 Pentapharm Ag Kosmetisch wirksame Zusammensetzung.
JP2002138027A (ja) * 2000-10-27 2002-05-14 Kose Corp 皮膚外用剤
US9155915B2 (en) * 2009-07-27 2015-10-13 Dermadoctor, Inc. Moisturizing retinol composition
US8410079B2 (en) * 2010-08-06 2013-04-02 Island Kinetics Chirally correct retinal cyclodextrin hemiacetals for clarifying skin complexion
EP2522330A1 (en) * 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and an edelweiss extract
FR2980361B1 (fr) * 2011-09-28 2013-10-25 Dermatologiques Uriage Lab Composition cosmetique et/ou dermatologique pour maintenir ou regenerer les qualites physiques, optiques, mecaniques ou biochimiques de la peau

Also Published As

Publication number Publication date
KR20160103983A (ko) 2016-09-02
EP3077061A1 (fr) 2016-10-12
RU2675702C1 (ru) 2018-12-24
ZA201603801B (en) 2017-07-26
PH12016501013A1 (en) 2016-07-04
WO2015082520A1 (fr) 2015-06-11
EP3077061B1 (fr) 2020-03-18
MX2016007295A (es) 2017-01-05
ES2791066T3 (es) 2020-10-30

Similar Documents

Publication Publication Date Title
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
ZA201600453B (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
EP3060685A4 (en) Methods of diagnosing and treating eosinophilic disorders
BR112018007356A2 (pt) métodos de produção de formas fucosiladas e não fucosiladas de uma proteína
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
BR112015009746A2 (pt) Agente que aumenta atividade de glicocerebrosidase em mamíferos
CL2015003704A1 (es) Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer
MX2015015249A (es) Peptidos terapeuticos.
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
DOP2016000006A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
EP3010938A4 (en) Fcrn-specific human antibody and composition for treatment of autoimmune diseases
BR112015024040A2 (pt) preparação alergênica
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
BR112013010556A2 (pt) métodos e composições adequadas para a promoção de uma pele saudável
BR112015030385A2 (pt) inibidores de pi3 delta e gama quinase seletivos duplos
WO2014145382A3 (en) Magnetoencephalography biomarkers of gaba-b agonist drug activity in autism spectrum disorders
BR112015029926A2 (pt) combinação de agentes ativos para o tratamento de envelhecimento da pele
MX370958B (es) Uso de alquilamidotiazoles en preparaciones cosméticas o dermatológicas para la profilaxis y el tratamiento de piel sensible.
BR112016026510A2 (pt) Dispositivo e formulação para tratamento tópico da dor que afeta a área vulvar do órgão genital feminino
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112016012671A2 (pt) Composição para reduzir distúrbios do envelhecimento da pele compreendendo um retinaldeído e um extrato de leontopodium alpinum
EP3011963A4 (en) Composition comprising filler and botulinum toxin for alleviating skin wrinkles or aging or treating neuromuscular diseases
BR112018008893A2 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica
EP2991733A4 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.